Asano K, Fumoto T, Matsuzaka M, Hasegawa S, Suzuki N, Akasaka K
BMC Cancer. 2021; 21(1):867.
PMID: 34320929
PMC: 8320052.
DOI: 10.1186/s12885-021-08592-z.
Joshi S, Cooke J, Ellis J, Emala C, Bruce J
J Neurooncol. 2017; 135(3):497-506.
PMID: 28875440
DOI: 10.1007/s11060-017-2615-5.
Lessov-Schlaggar C, Rubin J, Schlaggar B
Front Neurosci. 2016; 10:267.
PMID: 27375425
PMC: 4896944.
DOI: 10.3389/fnins.2016.00267.
Brandes A, Bartolotti M, Tosoni A, Franceschi E
Curr Neurol Neurosci Rep. 2016; 16(2):13.
PMID: 26750128
DOI: 10.1007/s11910-015-0611-8.
Grimm S, Chamberlain M
CNS Oncol. 2014; 1(1):49-70.
PMID: 25054300
PMC: 6176827.
DOI: 10.2217/cns.12.5.
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Batchelor T, Mulholland P, Neyns B, Nabors L, Campone M, Wick A
J Clin Oncol. 2013; 31(26):3212-8.
PMID: 23940216
PMC: 4021043.
DOI: 10.1200/JCO.2012.47.2464.
Paediatric and adult malignant glioma: close relatives or distant cousins?.
Jones C, Perryman L, Hargrave D
Nat Rev Clin Oncol. 2012; 9(7):400-13.
PMID: 22641364
DOI: 10.1038/nrclinonc.2012.87.
Role of bevacizumab therapy in the management of glioblastoma.
Peak S, Levin V
Cancer Manag Res. 2010; 2:97-104.
PMID: 21188100
PMC: 3004572.
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
Wick W, Puduvalli V, Chamberlain M, van den Bent M, Carpentier A, Cher L
J Clin Oncol. 2010; 28(7):1168-74.
PMID: 20124186
PMC: 2834468.
DOI: 10.1200/JCO.2009.23.2595.
Interrelationship between O6-alkylguanine-DNA alkyltransferase activity and susceptibility to chloroethylnitrosoureas in several glioma cell lines.
Hotta T, Saito Y, Mikami T, Kurisu K, Kiya K, Uozumi T
J Neurooncol. 1993; 17(1):1-8.
PMID: 8120566
DOI: 10.1007/BF01054267.
O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications.
Hotta T, Saito Y, Fujita H, Mikami T, Kurisu K, Kiya K
J Neurooncol. 1994; 21(2):135-40.
PMID: 7861189
DOI: 10.1007/BF01052897.
In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole.
Siemann D, Wolf K, Morrissey S, Wheeler K
Br J Cancer. 1984; 49(6):795-9.
PMID: 6733025
PMC: 1976855.
DOI: 10.1038/bjc.1984.123.
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Comella G, Scoppa G, De Marco M, Ianniello G, Melillo G, Coucourde F
J Neurooncol. 1985; 3(1):13-7.
PMID: 2987423
DOI: 10.1007/BF00165166.
BCNU stability as a function of ethanol concentration and temperature.
TEPE P, Hassenbusch S, Benoit R, Anderson J
J Neurooncol. 1991; 10(2):121-7.
PMID: 1895160
DOI: 10.1007/BF00146872.
Improved delivery through biological membranes. XLV. Synthesis, physical-chemical evaluation, and brain uptake studies of 2-chloroethyl nitrosourea delivery systems.
Raghavan K, Loftsson T, Brewster M, Bodor N
Pharm Res. 1992; 9(6):743-9.
PMID: 1409355
DOI: 10.1023/a:1015843219733.
